

CITATION REPORT

List of articles citing

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial

DOI: 10.1016/s0140-6736(20)31862-6
Lancet, The, 2020, 396, 959-967.

Source: <https://exaly.com/paper-pdf/76136143/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
244	Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?. 2020 , 101, 107-120		5
243	COVID-19 in Brazil: the headlines should be about science. <i>Lancet, The</i> , 2020 , 396, 1803	40	1
242	COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. 2020 , 45, 1		24
241	Drug treatments for covid-19: living systematic review and network meta-analysis. 2020 , 370, m2980		331
240	[COVID-19, management, therapeutic and vaccine approaches]. 2020 , 59, 27-33		1
239	Azithromycin for severe COVID-19. <i>Lancet, The</i> , 2020 , 396, 936-937	40	42
238	Rationale for COVID-19 Treatment by Nebulized Interferon-β-Literature Review and Personal Preliminary Experience. 2020 , 11, 592543		5
237	Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. 2021 , 75, e13896		8
236	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. 2021 , 133, 111008		14
235	Repurposing drugs for the management of COVID-19. 2021 , 31, 295-307		23
234	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of , , and clinical trials. 2021 , 11, 1207-1231		17
233	Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective. 2021 , 44, 95-105		7
232	Lines of Treatment of COVID-19 Infection. 2021 , 91-144		1
231	How glycobiology can help us treat and beat the COVID-19 pandemic. 2021 , 296, 100375		12
230	COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors. 2021 , 50, 740-749		5
229	Could repurposing existing vaccines and antibiotics help to control the COVID-19 pandemic?. 2021 , 245-255		
228	A literature review of consent declines and consent withdrawals in randomized controlled trials conducted during the COVID-19 pandemic. 2021 , 67, 134-138		1

227	Azithromycin Plus Zinc Sulfate Rapidly and Synergistically Suppresses IBβ-Mediated In Vitro Human Airway Cell ACE2 Expression for SARS-CoV-2 Entry.		2
226	Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan.		1
225	[S2k Guideline - Recommendations for Inpatient Therapy of Patients with COVID-19]. 2021 , 75, 88-112		14
224	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. 2021 , 325, 254-264		157
223	The Astronaut and the Jabuticaba. 2021 , 116, 1-3		
222	COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes. 2020 , 11, 599736		3
221	Bedside clinical data subphenotypes of critically ill COVID-19 patients: a cohort study. 2021 , 33, 196-205		
220	Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. 2021 , 49, 401-410		26
219	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. 2021 ,		28
218	Azithromycin, RECOVERY, and the power of large, simple trials. <i>Lancet, The</i> , 2021 , 397, 559-560	40	2
217	Clinical features and outcomes of hospitalized COVID-19 patients in a low burden region. 2021 , 115, 243-249		3
216	Clinical Characteristics and Outcome of Patients With Severe COVID-19 Pneumonia at a Public Sector Hospital in Karachi, Pakistan. 2021 , 13, e13107		5
215	Gestione del Covid-19 in età pediatrica: documento di consenso. 2021 , 40, 85-101		4
214	A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. 2021 , 12, 576448		5
213	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021 , 397, 605-612	40	117
212	Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis. 2021 , 32, 100743		8
211	A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of CCP collections. 2021 , 61, 1447-1460		7
210	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. 2021 , 895, 173890		41

209	Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. <i>Lancet, The</i> , 2021 , 397, 1063-1074	40	105
208	COVID-19, community trials, and inclusion. <i>Lancet, The</i> , 2021 , 397, 1036-1037	40	5
207	Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. 2021 , 33, 100773		28
206	Drug-Drug Interactions in Patients with COVID-19 in Nursing Homes. 2021 , 38, 633-635		
205	Current evidence for COVID-19 therapies: a systematic literature review. 2021 , 30,		11
204	Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists. 2021 , 41, 911-920		2
203	Case Report: A Severe SARS-CoV-2 Infection in a Teenager With Angelman Syndrome. 2021 , 8, 629112		
202	Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). <i>PLoS ONE</i> , 2021 , 16, e0248132	3.7	20
201	Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic. 2021 , 116, 872-879		1
200	Macrolides May Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Entry into Cells: A Quantitative Structure Activity Relationship Study and Experimental Validation. 2021 , 61, 2016-2025		2
199	COVID-19 therapeutics for low- and middle-income countries: a review of re-purposed candidate agents with potential for near-term use and impact.		1
198	Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19. 2021 , 25, 101549		5
197	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. 2021 , 57,		76
196	COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. 2021 , 254, 307-331		29
195	Temporal dynamics of the host molecular responses underlying severe COVID-19 progression and disease resolution. 2021 , 65, 103262		7
194	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. 2021 , 12, 632677		28
193	Repositioned Drugs for COVID-19-the Impact on Multiple Organs. 2021 , 3, 1-18		3
192	Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. 2021 , 9, 436-446		3

191	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. 2021 , 30, 694-706	13
190	An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. 2021 , 11, 9023	21
189	A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 in the ATOMIC2 trial.	2
188	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. 2021 , 104, 368504211016936	2
187	The time to offer treatments for COVID-19. 2021 , 30, 505-518	9
186	Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2. 2021 , 176, 1-12	39
185	Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications. 2021 , 14, 1487-1510	26
184	COVID-19 Management in the Pediatric Age: Consensus Document of the COVID-19 Working Group in Paediatrics of the Emilia-Romagna Region (RE-CO-Ped), Italy. 2021 , 18,	13
183	Review of Pharmacotherapy Tried for Management of the Coronavirus Disease-19. 2021 , 53, 137-143	2
182	Sub10 nm macroporous aramid substrates with a hierarchically structured interface for organic solvent nanofiltration. 2021 , 625, 119123	2
181	Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan. <i>PLoS ONE</i> , 2021 , 16, e0251754	3-7 7
180	In vitro safety "clinical trial" of the cardiac liability of drug polytherapy. 2021 , 14, 1155-1165	4
179	Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA Pandemic.	3
178	Azithromycin Use in COVID-19 Patients: Implications on the Antimicrobial Resistance. 2021 , 21, 677-683	2
177	Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic. 2021 , 4, e218828	43
176	How COVID-19 has fundamentally changed clinical research in global health. 2021 , 9, e711-e720	20
175	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. 2021 , 238, 569-578	0
174	Case Report: Development of Miliary Pulmonary Tuberculosis in a Patient with Peritoneal Tuberculosis after COVID-19 Upper Respiratory Tract Infection. 2021 ,	2

173	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. 2021 , 14, 601-621		29
172	Genetic susceptibility of COVID-19: a systematic review of current evidence. 2021 , 26, 46		27
171	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	10
170	Use of glucocorticoids and azithromycin in the therapy of COVID-19. 2021 , 73, 1513-1519		0
169	Clinical Management of COVID-19 Patients - An Update. 2022 , 52, 4-10		7
168	Characteristics and Clinical Course of Adult in Patients with SARS-CoV-2 Pneumonia at High Altitude. 2021 , 2021, 5590879		3
167	Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials. 2021 , e2258		10
166	Disputes over the production and dissemination of misinformation in the time of COVID-19. 2021 , 182, 106380		3
165	The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece. 2021 , 10, 1081-1095		0
164	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. 2021 , 18, 261-270		2
163	Antibacterial agents used in COVID-19: A systematic review and meta-analysis. 2021 , 4, 503-513		3
162	Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19. 2021 , 53, 508-541		
161	Update in COVID-19 2020. 2021 , 203, 1462-1471		5
160	An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan. 2021 , 10,		11
159	The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome. 2021 , 8, 671714		7
158	PRINCIPLE trial demonstrates scope for in-pandemic improvement in primary care antibiotic stewardship: a retrospective sentinel network cohort study. 2021 , 5,		5
157	[Critical patients COVID-19 Has changed the management and outcomes in the ICU after 1 year of the pandemic?A multicenter, prospective, observational study]. 2021 ,		
156	One Year of the COVID-19 Pandemic. What Do We Know and What Is Yet to Come? - The Summarising Review. 2021 , 66, 1603975		0

155	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. 2021 , 19, 1219-1244	3
154	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). 2021 , 10, 1837-1885	10
153	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. 2021 , 2021, 1-22	0
152	Surveillance of Antibacterial Usage during the COVID-19 Pandemic in England, 2020. 2021 , 10,	14
151	Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021). 2021 , 1	6
150	Association between Early Antibiotic Therapy and In-Hospital Mortality among Older Patients with SARS-CoV-2 Pneumonia. 2021 ,	2
149	The Effect of Azithromycin Plus Zinc Sulfate on ACE2 Expression through IB of Human Respiratory Cells in SARS-CoV-2: In Vitro Study. 2021 , 1, 263-275	0
148	A critical review on environmental presence of pharmaceutical drugs tested for the covid-19 treatment. 2021 , 152, 568-582	10
147	NSAIDs and COVID-19: A Systematic Review and Meta-analysis. 2021 , 44, 929-938	19
146	Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection. 2021 , 905, 174191	8
145	Effects of Hydroxychloroquine and Azithromycin on iPSC-derived Cardiomyocytes: Considerations for the Treatment of COVID-19 Patients.	1
144	Sars-Cov-2 Infection in Patients on Long-Term Treatment with Macrolides in Spain: A National Cross-Sectional Study. 2021 , 10,	0
143	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. 2021 , 93, 6737-6749	4
142	Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial. 2021 , 10, 2333-2351	3
141	Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulation cOroNavius)-Coalition IV trial. 2021 , 238, 1-11	10
140	COVID-19: potential therapeutics for pediatric patients. 2021 , 73, 1520-1538	6
139	Heart Muscle Microphysiological System for Cardiac Liability Prediction of Repurposed COVID-19 Therapeutics. 2021 , 12, 684252	3
138	Azithromycin in patients with Covid-19; a systematic review and metanalysis.	1

137	A metaresearch study revealed susceptibility of Covid-19 treatment research to white hat bias: first, do no harm. 2021 , 136, 55-63	6
136	Current status of therapeutic alternatives for COVID-19: A narrative review.. 2021 , 29, 312-327	2
135	Antibiotics against viruses: Brazilian doctors adrift. 2021 , 1-2	1
134	COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact. 2021 , 105, 584-595	3
133	Does COVID-19 pneumonia signify secondary organizing pneumonia?: A narrative review comparing the similarities between these two distinct entities. 2021 , 50, 667-674	5
132	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. 2021 , 9, 729559	7
131	Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID-19 study). 2021 , 11, e053325	0
130	A hitchhiker's guide through the COVID-19 galaxy. <i>Clinical Immunology</i> , 2021 , 232, 108849	9 0
129	Myasthenia gravis and covid-19 in pregnancy: a review of the literature and case series report. 2021 , 1-9	1
128	Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study. 2021 , 14, 5597-5606	2
127	Pharmacotherapy of atrial fibrillation in COVID-19 patients. 2021 , 28, 758-766	1
126	Bacterial Coinfections in Coronavirus Disease 2019. 2021 , 29, 930-941	26
125	Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. 2021 , 9, 1130-1140	25
124	Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis. 2021 , 84, 299-316	5
123	Abstracts for reports of randomised trials of COVID-19 interventions had low quality and high spin. 2021 , 107-120	4
122	Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. 2021 , 139, 68-79	3
121	Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study. 2021 , 62, 799-805	1
120	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. 2021 , 372, n84	186

119	Computational analysis of macrolides as SARS-CoV-2 main protease inhibitors: a pattern recognition study based on molecular topology and validated by molecular docking. 2021 , 45, 8654-8675	1
118	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. 2021 , 53, 166-219	11
117	Rationale for azithromycin in COVID-19: an overview of existing evidence. 2021 , 8,	23
116	Progresses in clinical studies on antiviral therapies for COVID-19-Experience and lessons in design of clinical trials. 2020 , 4, 263-274	3
115	Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru.	3
114	Correlation of Body Mass Index (BMI), initial neutralizing antibodies (nAb), ABO group and kinetics of nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibodies in convalescent plasma (CCP) donors [A longitudinal study with proposals for better quality of CCP collections.	1
113	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).	2
112	Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.	4
111	In Vitro Safety "Clinical Trial" of the Cardiac Liability of Hydroxychloroquine and Azithromycin as COVID19 Polytherapy. 2020 ,	3
110	Early start of oral clarithromycin is associated with better outcome in COVID-19 of moderate severity: the ACHIEVE open-label trial.	3
109	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. 2020 , 13, 4673-4695	20
108	Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. 2020 ,	3
107	Azithromycin in patients with COVID-19: a systematic review and meta-analysis. 2021 ,	2
106	Antibiotics for the treatment of COVID-19. 2021 , 10, CD015025	10
105	Microbial coinfections and superinfections in critical COVID-19: a Kenyan retrospective cohort analysis. 2021 , 1, 41-46	1
104	Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. 2021 ,	0
103	Combating Oxidative Stress and Inflammation in COVID-19 by Molecular Hydrogen Therapy: Mechanisms and Perspectives. 2021 , 2021, 5513868	16
102	Characteristics and Outcomes of US Patients Hospitalized With COVID-19. 2021 , e1-e12	1

101	The Impact of COVID-19 on Outpatient Antibiotic Prescriptions in Ontario, Canada; An Interrupted Time Series Analysis. 2021 , 8, ofab533		6
100	Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020.		0
99	Current evidence for COVID-19 therapies: a systematic literature review.		
98	Clarithromycin use for adjunct surgical prophylaxis before non-elective cesarean deliveries to adapt to azithromycin shortages in COVID-19 pandemic. <i>PLoS ONE</i> , 2020 , 15, e0244266	3.7	1
97	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.		
96	A Systematic Review and Network Meta-Analysis for COVID-19 Treatments.		
95	Adverse drug reactions and drug interactions in the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). 2021 , 1,		1
94	Perfil clínico e fatores associados ao Bito de pacientes COVID-19 nos primeiros meses da pandemia. 26,		3
93	Pharmacotherapy of COVID-19: Considerations for Pregnancy and Breastfeeding. 2022 , 7, 1-6		1
92	Critical Care for COVID-19 Affected Patients: Updated Position Statement of the Indian Society of Critical Care Medicine. 2020 , 24, S225-S230		2
91	The immunomodulatory effects of macrolide antibiotics in respiratory disease. 2021 , 71, 102095		5
90	Host-modifying drugs against COVID-19: some successes, but not yet the breakthrough. 2021 ,		
89	Clinical features and mechanistic insights into drug repurposing for combating COVID-19. 2021 , 142, 106114		6
88	Self-medication practices to prevent or manage COVID-19: A systematic review. <i>PLoS ONE</i> , 2021 , 16, e0259317	3.7	10
87	Clinical Trials in COVID-19 Management & Prevention: A Meta-epidemiological Study examining methodological quality.		
86	Role of azithromycin in antiviral treatment: enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade?. 2020 , 12, 7702-7708		4
85	Quality of life and long-term outcomes after hospitalization for COVID-19: Protocol for a prospective cohort study (Coalition VII). 2021 , 33, 31-37		
84	ESCMID COVID-19 Living guidelines: drug treatment and clinical management. 2021 ,		16

83	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. 2021 , 10, 1-32		0
82	Many Trials of Hydroxychloroquine for SARS-CoV-2 Were Redundant and Potentially Unethical: An Analysis of the NIH Clinical Trials Registry. 2021 ,		0
81	Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. 2021 , 71, 39		3
80	Analysis of the Prescription of Antibiotics During the Implementation of COVID-19 Personal Protection Measures in a Regional Health System. 2021 , 13, 927-936		0
79	Photo-mediated and advanced oxidative processes applied for the treatment of effluents with drugs used for the treatment of early COVID-19: Review. 2021 , 6, 100140		0
78	Continued use of azithromycin for mild COVID-19 in India: Evidence and implications?. 2021 , 10, 4341-4344		0
77	Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis.. 2022 , 1		2
76	COVID-19 in Children and Adolescents: Characteristics and Specificities in Immunocompetent and Oncohematological Patients.. 2022 , 14, e2022009		1
75	Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19.. <i>PLoS ONE</i> , 2022 , 17, e0262777	3.7	2
74	Repurposing Covid-19 Drug : Current Issues. 2022 , 13, 9-16		
73	Multiple secondary outcome analyses: precise interpretation is important.. 2022 , 23, 27		1
72	Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials.. 2022 , 22, 107		7
71	Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO).. 2022 , 8,		1
70	Clinical outcomes of immunomodulatory therapies in the management of COVID-19: A tertiary-care experience from Pakistan.. <i>PLoS ONE</i> , 2022 , 17, e0262608	3.7	0
69	Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020.. <i>PLoS ONE</i> , 2022 , 17, e0263437	3.7	4
68	Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.. 2022 , 12, e051579		1
67	Antiviral effects of azithromycin: A narrative review.. 2022 , 147, 112682		1
66	Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: a network meta-analysis of randomised controlled trials. 2021 ,		3

65	The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline.. 2021 , 30,		3
64	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants.. 2022 , 11,		4
63	Synergistic Adverse Effects of Azithromycin and Hydroxychloroquine on Human Cardiomyocytes at a Clinically Relevant Treatment Duration.. <i>Pharmaceuticals</i> , 2022 , 15,	5.2	1
62	Evolution of prescribing practices and outcomes in the COVID-19 pandemic in metropolitan areas.. 2022 , 30, 86-95		
61	Antibiotic prescribing patterns among patients admitted to an academic teaching hospital for COVID-19 during the first wave of the pandemic in Toronto: A retrospective, controlled study. 2022 , 7, 14-22		
60	Consumption Trends of Antibiotics in Brazil During the COVID-19 Pandemic.. 2022 , 13, 844818		4
59	Pharmacological consideration of COVID-19 infection and vaccines in pregnancy.. 2022 ,		1
58	Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study.. 2022 , 11,		0
57	Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.. 2022 , 184, 114252		0
56	A critical analysis about the supposed role of azithromycin in the treatment of covid-19. 2021 , 11, 11-21		
55	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. 2021 ,		3
54	Drug repurposing strategies and key challenges for COVID-19 management. 2021 , 1-17		4
53	Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists.. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	2
52	Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study.. 2022 , 1		2
51	Beneficial ex vivo immunomodulatory and clinical effects of clarithromycin in COVID-19.. 2022 ,		
50	Can We Really Trust the Findings of the COVID-19 Research? Quality Assessment of Randomized Controlled Trials Published on COVID-19.		
49	datasheet1.pdf. 2020 ,		
48	Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP).. 2022 , 134, 399		

47	Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs.. 2022 , 93, e2022014		1
46	The effect of outpatient antibiotic treatment of coronavirus disease 2019 on the outcomes in the emergency department: a propensity score matching study.. 2022 , 63, 53-61		
45	Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update.. <i>Clinical Immunology</i> , 2022 , 109022	9	2
44	Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic.. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022 ,	1.6	0
43	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 634	5.2	1
42	Antibiotic Prescription and in-Hospital Mortality in COVID-19: A Prospective Multicentre Cohort Study. <i>Journal of Personalized Medicine</i> , 2022 , 12, 877	3.6	1
41	Calibration and Validation of a Mechanistic COVID -19 Model for Translational Quantitative Systems Pharmacology [A Proof-of-Concept Model Development for Remdesivir. <i>Clinical Pharmacology and Therapeutics</i> ,	6.1	0
40	The indiscriminate use of azithromycin during COVID-19 era: A potential driver for antimicrobial resistance. <i>Annals of Medicine and Surgery</i> , 2022 , 103957	2	
39	Death and invasive mechanical ventilation risk in hospitalized COVID-19 patients treated with anti-SARS-CoV-2 monoclonal antibodies and/or antiviral agents: A systematic review and network meta-analysis protocol. <i>PLoS ONE</i> , 2022 , 17, e0270196	3.7	0
38	Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey. <i>Microorganisms</i> , 2022 , 10, 1284	4.9	1
37	The Intersection between Heart Failure and Critical Care Cardiology: An International Perspective on Structure, Staffing, and Design Considerations. <i>Journal of Cardiac Failure</i> , 2022 ,	3.3	
36	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper. <i>Journal of Hepatology</i> , 2022 ,	13.4	0
35	Critical patients COVID-19 has changed the management and outcomes in the ICU after 1 year of the pandemic? A multicenter, prospective, observational study. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2022 ,	0.1	
34	Azithromycin through the Lens of the COVID-19 Treatment. 2022 , 11, 1063		1
33	Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis.		1
32	The scenario of self-medication practices during the covid-19 pandemic; a systematic review. 2022 , 82, 104482		2
31	Azithromycin use and outcomes in patients with COVID-19: an observational real-world study. 2022 , 124, 27-34		0
30	Pre-hospital Management of COVID-19: Looking for a Future Perspective. 2022 , 395-419		0

29	The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort. 9,	0
28	COVID-19 and Pulmonary Diseases. 2022 , 230-262	0
27	Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review. 2022 , 12,	1
26	Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. 2022 , 12, 1456	0
25	Evolution of Care and Outcomes Across Surges in Hospitalized Patients with Coronavirus Disease 2019. 2022 ,	0
24	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. 2022 , 20,	0
23	Care for adults with COVID -19: living guidelines from the National COVID -19 Clinical Evidence Taskforce. 2022 , 217, 368-378	1
22	Approaches to Assessing the Safety of Medicines during the COVID-19 Pandemic Using the Example of Azithromycin. 2022 , 10, 283-292	0
21	Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials. 2022 , 101, e30998	0
20	A systematic review of acute and emergency care interventions for adolescents and adults with severe acute respiratory infections including COVID-19 in low- and middle-income countries. 12,	0
19	Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients. 13,	1
18	Life stressors significantly impact long-term outcomes and post-acute symptoms 12-months after COVID-19 hospitalization. 2022 , 443, 120487	2
17	Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. 2022 , 20,	1
16	Comparison of methylprednisolone pulse vs conventional dexamethasone for adult cases of COVID-19 requiring oxygen; a Japanese retrospective cohort study. 2022 ,	0
15	Utilization of Antibiotics for Hospitalized Patients with Severe Coronavirus Disease 2019 in Al-Madinah Al-Munawara, Saudi Arabia: A Retrospective Study. Volume 15, 7401-7411	0
14	Antibiotics Use in COVID-19 Patients: A Systematic Literature Review. 2022 , 11, 7207	0
13	Probing the neuro-psychological changes observed with the administration of COVID-19 Drugs. 2022 , 23,	1
12	The outcome of Covid-19 Infection on Kidney Transplantation Recipients in Southern Saudi Arabia, Single Center Experience. 2023 ,	0

11	Association between acute disease severity and one-year quality of life among post-hospitalisation COVID-19 patients: Coalition VII prospective cohort study.	0
10	COVID-19: Cardiology Perspective. 2023 , 361-388	0
9	Pharmacologic Therapeutics for COVID-19. 2023 , 290-318	0
8	COVID-19: Inpatient Management. 2023 , 182-232	0
7	The development of COVID-19 treatment. 14,	2
6	An overview on the treatments and prevention against COVID-19. 2023 , 20,	0
5	Dry powder formulation of azithromycin for COVID-19 therapeutics. 1-16	0
4	Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: Fundamenta e Desenho do Estudo CARE (CARE [Coalition COVID-19 Brazil VIII]). 2023 , 120,	0
3	Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review. 14,	0
2	Iniciativas Brasileiras Lideram com Forte Coopera Cientica para Enfrentar Questes da COVID-19: O Caso da Coaliz COVID-19 Brasil. 2023 , 120,	0
1	Antihistamines as an early treatment for Covid-19. 2023 , 9, e15772	0